Profound Medical Q4 2023 Earnings Report

Profound Medical EPS Results

• Actual EPS: -$0.42
• Consensus EPS: -$0.28
• Beat/Miss: Missed by -$0.14
• One Year Ago EPS: N/A

Profound Medical Revenue Results

• Actual Revenue: $2.01 million
• Expected Revenue: $1.90 million
• Beat/Miss: Beat by +$110.00 thousand
• YoY Revenue Growth: N/A

Profound Medical Announcement Details

• Quarter: Q4 2023
• Date: 3/7/2024
• Time: N/A

Profound Medical (NASDAQ:PROF), together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.